| 1 |
Su C. Stronger Neo‐Minophagen C ( SNMC ): A stronger adjuvant for TACE ? Adv in Digestive Medicine 2023;10:5-7. [DOI: 10.1002/aid2.13361] [Reference Citation Analysis]
|
| 2 |
Huang W, Lin Y, Kuo H, Sheu M, Feng Y, Feng I, Sun C, Hsieh P, Lim P, Chen C. Benefits of stronger Neo‐Minophagen C in acute hepatitis after transarterial chemoembolization therapy for hepatomas. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13305] [Reference Citation Analysis]
|
| 3 |
Wahab S, Annadurai S, Abullais SS, Das G, Ahmad W, Ahmad MF, Kandasamy G, Vasudevan R, Ali MS, Amir M. Glycyrrhiza glabra (Licorice): A Comprehensive Review on Its Phytochemistry, Biological Activities, Clinical Evidence and Toxicology. Plants (Basel) 2021;10:2751. [PMID: 34961221 DOI: 10.3390/plants10122751] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 4 |
Manivannan S, Wales E, Zaben M. The Role of HMGB1 in Traumatic Brain Injury-Bridging the Gap Between the Laboratory and Clinical Studies. Curr Neurol Neurosci Rep 2021;21:75. [PMID: 34870759 DOI: 10.1007/s11910-021-01158-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Yamazaki T, Joshita S, Ichijo T, Kobayashi H, Wakabayashi SI, Yamashita Y, Sugiura A, Kawakami F, Nakazawa H, Umemura T. Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature. J Infect Chemother 2021;27:1750-5. [PMID: 34344581 DOI: 10.1016/j.jiac.2021.07.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Pun CK, Huang HC, Chang CC, Chuang CL, Yen CH, Hsu SJ, Lee FY, Hou MC, Huang YH. Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats. Int J Mol Sci 2021;22:7662. [PMID: 34299285 DOI: 10.3390/ijms22147662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem 2021;224:113690. [PMID: 34256124 DOI: 10.1016/j.ejmech.2021.113690] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 8 |
Okovity SV, Raikhelson KL, Volnukhin AV, Kudlai DA. Hepatoprotective properties of glycyrrhizic acid. jour 2020. [DOI: 10.31146/1682-8658-ecg-184-12-96-108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 9 |
Dang XL, Yang LF, Shi L, Li LF, He P, Chen J, Zheng BJ, Yang P, Wen AD. Post-treatment with glycyrrhizin can attenuate hepatic mitochondrial damage induced by acetaminophen in mice. Exp Biol Med (Maywood) 2021;246:1219-27. [PMID: 33342284 DOI: 10.1177/1535370220977823] [Reference Citation Analysis]
|
| 10 |
Qian Y, Markowitz JS. Natural Products as Modulators of CES1 Activity. Drug Metab Dispos 2020;48:993-1007. [PMID: 32591414 DOI: 10.1124/dmd.120.000065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Bailly C, Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol Ther. 2020;214:107618. [PMID: 32592716 DOI: 10.1016/j.pharmthera.2020.107618] [Cited by in Crossref: 136] [Cited by in F6Publishing: 144] [Article Influence: 45.3] [Reference Citation Analysis]
|
| 12 |
Kwon YJ, Son DH, Chung TH, Lee YJ. A Review of the Pharmacological Efficacy and Safety of Licorice Root from Corroborative Clinical Trial Findings. J Med Food 2020;23:12-20. [PMID: 31874059 DOI: 10.1089/jmf.2019.4459] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 13 |
Ayoub M, Shinde-Jadhav S, Mansure JJ, Alvarez F, Connell T, Seuntjens J, Piccirillo CA, Kassouf W. The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance. Sci Rep 2019;9:6348. [PMID: 31015520 DOI: 10.1038/s41598-019-42864-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 14 |
Li X, Sun R, Liu R. Natural products in licorice for the therapy of liver diseases: Progress and future opportunities. Pharmacol Res 2019;144:210-26. [PMID: 31022523 DOI: 10.1016/j.phrs.2019.04.025] [Cited by in Crossref: 97] [Cited by in F6Publishing: 105] [Article Influence: 24.3] [Reference Citation Analysis]
|
| 15 |
Wang S, Sheu M, Kuo H, Lin C, Sun C, Feng I. Intravenous glycyrrhizin as a rescue therapy in a patient with latent hepatitis B virus reactivation and acute severe decompensation induced by chemotherapy with rituximab. Adv in Digestive Med 2019;6:77-80. [DOI: 10.1002/aid2.13117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 16 |
Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int 2019;39:31-41. [PMID: 30003672 DOI: 10.1111/liv.13931] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 17 |
Komatsu A, Yoshino T, Suzuki T, Nakamura T, Kanai T, Watanabe K. Risk factors associated with pseudoaldosteronism in patients with chronic hepatitis: A retrospective cohort study. Basic Clin Pharmacol Toxicol 2019;124:607-14. [DOI: 10.1111/bcpt.13178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Rouhiainen A, Nykänen NP, Kuja-Panula J, Vanttola P, Huttunen HJ, Rauvala H. Inhibition of Homophilic Interactions and Ligand Binding of the Receptor for Advanced Glycation End Products by Heparin and Heparin-Related Carbohydrate Structures. Medicines (Basel) 2018;5:E79. [PMID: 30061484 DOI: 10.3390/medicines5030079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 19 |
Fox CJ, Cornett EM, Hart BM, Kaye AJ, Patil SS, Turpin MC, Valdez A, Urman RD, Kaye AD. Pulmonary vasodilators: Latest evidence and outcomes in the perioperative setting. Best Pract Res Clin Anaesthesiol 2018;32:237-50. [PMID: 30322463 DOI: 10.1016/j.bpa.2018.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
